June 30, 2026 05:33 am (IST)
Follow us:
Dr Reddy's acquires rights to an investigational anti-cancer agent
Hyderabad, Mar 31 (IBNS) Dr Reddy's Laboratories, an integrated pharmaceutical company, announced on Thursday that it has entered into a licensing agreement with Eisai Company Limited of Japan, by which Dr Reddy's will be granted exclusive worldwide development and commercialization rights (excluding Japan and Asia) for Eisai's investigational anticancer agent E7777.
Eisai will develop and market E7777 in Japan and Asia; Dr Reddy's holds the option for rights to develop and market the agent in India, the company said.
In exchange of these rights, Eisai will receive milestone payments in line with obtaining marketing approval and the achievement of agreed upon sales targets.
Raghav Chari, Executive Vice President, Proprietary Products Group, Dr Reddy's Laboratories, said, "E7777 has significant potential as an important component of systemic therapy for cutaneous T-cell lymphoma (CTCL). This therapy represents an extension of our current efforts in the dermatology space to an important segment of skin-related cancers."
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
From Mumbai teen to AI trailblazer: Meet 19-year-old Dhravya Shah behind Supermemory's $3 million funding
Mon, Jun 29 2026
Stop exchanging currency! You can use UPI app in Seychelles in future. List of other nations where the app can be used
Mon, Jun 29 2026
Why did Kotak Mahindra Bank stock fall 3% today? CEO Ashok Vaswani's decision explained
Mon, Jun 29 2026
India overtakes Taiwan, South Korea to become world's fifth-largest equity market again
Mon, Jun 29 2026
Best Car Insurance for Cars Driven Less Than 5,000 KM a Year
Sat, Jun 27 2026